Biotherapeutic
- Business Wire
Ferring and Rebiotix Present Landmark Phase 3 Data Demonstrating Superior Efficacy of Investigational RBX2660 Versus Placebo to Reduce Recurrence of C. difficile Infection
RBX2660 pivotal Phase 3 trial successfully met the primary endpoint; data presented today at Digestive Disease Week® (DDW) RBX2660 is…
Read More » - World
Ferring and Rebiotix to Present Landmark Data for Investigational Microbiota-based Live Biotherapeutic RBX2660 at Digestive Disease Week® (DDW) 2021
Saint-Prex, Switzerland & Roseville, Minn., United States: For the first time ever, Ferring and Rebiotix, a Ferring Company, will present…
Read More » - Technology
Waters Peptide Multi-Attribute Method for BioAccord System Boosts Innovator and Biosimilar Drug Development and Commercialization
Milford, Mass., United States: NEWS SUMMARY: New Peptide MAM (multi-attribute method) workflow for the BioAccord LC-MS System monitors product quality…
Read More »